Validation Of mRNA Concentration Determination Using Variable Pathlength Spectroscopy

Developing mRNA-based therapeutics requires comprehensive analytical testing in order to meet regulatory requirements. However, developers face the challenge of balancing pre-clinical and clinical testing with the need to remain competitive in the market. Optimizing processes to ensure analytical testing results are fast and reliable is critical as you bring your product to market.

Travis Alvine, Ph.D., Senior Manager for Analytical Method Validation, Aldevron, and Joe Ferraiolo, Director of Bioanalytical Applications, Repligen, discuss considerations for variable pathlength technology as well as the importance of ensuring regulatory compliance and prioritizing quality and patient safety.